利格列汀联合胰激肽酶原治疗2型糖尿病对动态血糖的影响

Clinical Effect of Legliptin Combined with Trypsin Proplasminogen in the Treatment of Type 2 Diabetes Mellitus and Its Effect on Dynamic Blood Glucose

目的观察利格列汀联合胰激肽酶原治疗2型糖尿病的效果及对患者动态血糖水平的影响。方法选取医院2015年12月至2017年2月收治的2型糖尿病患者120例,按随机数字表法分为对照组和研究组,各60例。两组患者均行常规治疗,对照组加用利格列汀,研究组在对照组治疗基础上联合胰激肽酶原治疗。结果治疗后,两组患者空腹血糖(FBG)、糖化血红蛋白(HbA_(1C))、餐后2 h血糖(2 hPG)及体质量指数(BMI)均明显降低,且研究组降低幅度更大(P<0.05);研究组患者血糖控制情况及动态血糖改善情况均明显优于对照组(P<0.05);研究组不良反应发生率为10.00%,明显低于对照组的26.67%(P<0.05)。结论利格列汀联合胰激肽酶原治疗2型糖尿病可有效改善患者的动态血糖,实现血糖控制标准,提高治疗安全性,值得推广。

Objective To observe the clinical effect of legliptin combined with trypsin proplasminogen in the treatment of type 2 diabetes mellitus（T2DM） and its effect on dynamic blood glucose. Methods Totally 120 patients with T2DM admitted to our hospital from December 2015 to February 2017 were selected and divided into the control group and the study group according to the random number table method,60 cases in each group. The two groups were treated with conventional therapy,on this basis,the control group was treated with linagliptin,while the study group was treated with linagliptin combined with trypsin proplasminogen. Results After treatment,the FBG,HbA_（1C）,2 h PG and BMI of the two groups were significantly decreased,and the decrease in the study group was more significant（P〈0. 05）. The control of blood glucose and the improvement of dynamic blood glucose in the study group were significantly better than that in the control group（P〈0. 05）. The incidence rate of adverse reactions in the study group was 10. 00%,which was significantly lower than 26. 67% in the control group（P〈0. 05）. Conclusion Legletine combined with trypsin proplasminogen in the treatment of T2DM can effectively improve the dynamic blood glucose,achieve the control standard of blood sugar,improve the safety of treatment,which is worthy of promotion.